Medicine and Dentistry
Adverse Event
14%
Allotransplantation
24%
Arm
27%
B Cell
20%
B-Cell Chronic Lymphocytic Leukemia
40%
B-Cell Lymphoma
17%
Bone Marrow Transplantation
13%
Brentuximab Vedotin
13%
Cancer
15%
Chemotherapy-Induced Peripheral Neuropathy
17%
Classical Hodgkin Lymphoma
23%
Clinical Trial
21%
Cumulative Incidence
16%
Cyclophosphamide
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
18%
Diffuse Large B-Cell Lymphoma
33%
Disease
37%
Doxorubicin
18%
Drug Megadose
32%
Follicular Lymphoma
23%
Graft Versus Host Reaction
54%
Haploidentical Transplantation
17%
Hazard Ratio
32%
Hematologic Malignancy
14%
Hodgkin's Lymphoma
34%
Human Immunodeficiency Virus
23%
Idelalisib
40%
Immunoglobulin
17%
Immunosuppressive Treatment
17%
Infusion
16%
Lenalidomide
34%
Lymphocytic Lymphoma
24%
Malignant Neoplasm
33%
Mantle Cell Lymphoma
17%
Methotrexate
15%
Neoplasm
13%
Non-Hodgkin Lymphoma
29%
Nonmyeloablative Conditioning
19%
Oncology
26%
Overall Survival
64%
Positron Emission Tomography
15%
Prednisone
15%
Progression Free Survival
65%
Prophylaxis
32%
Recurrence Free Survival
13%
Rituximab
55%
Stem Cell Transplant
16%
Transplantation
43%
Vincristine
18%
Whole Body Radiation
14%
Keyphrases
Acute Lymphoblastic Leukemia
11%
Adverse Events
15%
Allogeneic Blood or Marrow Transplantation
42%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
27%
Allogeneic Transplantation
28%
Blood or Marrow Transplantation
12%
Brentuximab Vedotin
14%
Chemotherapy
15%
Chemotherapy-induced Peripheral Neuropathy
17%
Chronic Lymphocytic Leukemia
43%
Classic Hodgkin Lymphoma
17%
Confidence Interval
46%
Cumulative Incidence
13%
Cyclophosphamide
12%
Diffuse Large B-cell Lymphoma (DLBCL)
15%
Follicular Lymphoma
19%
Graft-versus-host Disease (GvHD)
45%
Graft-versus-host Disease Prophylaxis
25%
Haploidentical Transplantation
15%
Hazard Ratio
17%
High Dose
13%
High-dose Methotrexate (HD-MTX)
13%
Idelalisib
28%
Immunoglobulin
11%
Immunosuppressive Therapy
14%
Indolent Lymphoma
13%
Indolent non-Hodgkin Lymphoma
15%
Lenalidomide
28%
Lymphoma
27%
Lymphoma Patients
23%
Maintenance Therapy
12%
Mantle Cell Lymphoma
15%
Myeloablative Conditioning
12%
Neuropathy
12%
Neurotoxic Chemotherapy
11%
Non-relapse Mortality
16%
Nonmyeloablative
28%
Overall Response Rate
15%
Overall Survival
47%
Peripheral Blood
17%
Phase II Study
20%
Post-transplantation Cyclophosphamide (PTCy)
84%
Progression-free Survival
30%
Relapse-free Survival
18%
Relapsed Lymphoma
22%
Relapsed or Refractory
58%
Retrospective Analysis
13%
Rituximab
36%
Severe Aplastic Anemia
11%
Transplantation
13%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Versus Host Disease
8%
Adverse Event
22%
Aplastic Anemia
11%
B Cell Lymphoma
8%
Bruton Tyrosine Kinase Inhibitor
7%
Chemotherapy
42%
Chemotherapy-Induced Peripheral Neuropathy
19%
Chimeric Antigen Receptor
8%
Chronic Lymphatic Leukemia
37%
Classical Hodgkin Lymphoma
23%
Clinical Trial
19%
Cyclophosphamide
85%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
12%
Diffuse Large B Cell Lymphoma
41%
Disease
47%
Doxorubicin
23%
Etoposide
12%
Follicular Lymphoma
22%
Graft Failure
10%
Graft Versus Host Reaction
38%
Hematologic Malignancy
17%
HIV
11%
Hodgkin Disease
11%
Idelalisib
40%
Immunosuppressive Agent
8%
Inotuzumab Ozogamicin
11%
Lenalidomide
28%
Lymphocytic Lymphoma
12%
Malignant Neoplasm
27%
Mantle Cell Lymphoma
9%
Methotrexate
25%
Neoplasm
13%
Neuropathy
18%
Neutropenia
10%
Nonhodgkin Lymphoma
38%
Ofatumumab
17%
Overall Survival
52%
Oxaliplatin
14%
Oxaliplatin-Induced Neuropathy
12%
Paclitaxel
15%
Phosphatidylinositol 3 Kinase
17%
Prednisone
14%
Progression Free Survival
48%
Recurrence Free Survival
7%
Remission
9%
Rituximab
56%
Symptom
16%
Thrombocytopenia
8%
Tolerability
12%
Vincristine
22%